Trial Profile
A Single-centre, retrospective study to evaluate selexipag in patients with Eisenmenger Syndrome associated with congenital heart disease
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 12 Jul 2017
Price :
$35
*
At a glance
- Drugs Selexipag (Primary)
- Indications Congenital heart defects; Eisenmenger complex
- Focus Therapeutic Use
- 12 Jul 2017 New trial record
- 24 May 2017 Results (n=4) presented at the 113th International Conference of the American Thoracic Society